Monoamine oxidase A (MAOA) is an enzyme involved in the metabolism of the monoamines, eg 5-HT and noradrenaline. It converts the monoamines into their corresponding carboxylic acid via an aldehyde intermediate. MAOA regulates both the free intraneuronal concentration and the releasable stores of 5-HT and noradrenaline. MAOA inhibitors bind to and inhibit MAOA, preventing monoamine degradation. This results in greater stores of monoamines available for release. MAOA inhibitors are used in the treatment of depression. It has been proposed that MAO inhibitors treat depression by preventing monoamine degradation and delaying downregulation of beta-andrenoceptors and 5-HT2 receptors.
Click here: Discover the role of MAO-A inhibitors in depression treatment
Related content
This slide deck summarizes the current knowledge surrounding the use of psychedelics for the treatment of depression. Specifically, our focus centers on serotonergic psychedelics, commonly referred to as classical psychedelics. These psychedelics primarily function as agonists or partial agonists at the serotonin 2A receptor (5-HT2A receptor).
The infographic shows a 27% increase in depression cases due to COVID-19, affecting 280 million people worldwide.
Dr. Jasmina Mallet highlights the latest research in psychiatric genetics, emphasizing the role of Polygenic Risk Scores (PRS) in psychiatry.